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Aim: In this study, we aim to construct nanoformulation with high-cargo loading 
and controlled serum kinetics. Materials & methods: Molecular-matched materials 
(MMMs) are established through the conjugation of the functional moiety to a 
molecule representative of the nanoparticle’s core. Molecular-matched nanoemulsions 
and liposomes were prepared using MMMs. Results: This technique based on MMMs 
even allows us to efficiently load either hydrophobic or hydrophilic moieties into a 
hydrophobic core of the nanoparticles. MMMs-based nanoparticles showed marked 
improvement in serum pharmacokinetics and anticancer effect. Conclusion: The 
desired performance can be achieved when the hydrophobic anchor of the PEG 
derivatives and the moiety conjugated to the therapeutic (or imaging) agents are 
molecularly identical to the core.
Keywords: imaging • long circulation • molecular-matched nanoparticles • paclitaxel  
• PEGylation
Nanocarriers designed with hydrophobic 
cores are often useful for delivering hydro-
phobic drugs but are highly incompatible 
with hydrophilic imaging probes. Addition-
ally, highly crystalline hydrophobic drugs, 
such as paclitaxel (PTX), may also be 
incompatible with these particles. This leads 
to issues with cargo selectivity and load-
ing efficiency. Other common issues with 
nanocarriers are uncontrolled cargo release 
or rapid pharmacokinetic (PK) clearance. 
Great efforts have been made to remedy these 
problems; however, no carrier has effectively 
managed all these issues [1–5]. While many 
different formulations have been applied to 
PTX, there has been very little success thus 
earning it the description ‘brickdust’ [6]. As 
to PTX formulation, only Taxol and Abrax-
ane were approved by the US FDA for can-
cer therapy, but both have some limitations. 
Taxol requires the use of Cremophor-EL at a 
ratio of PTX to surfactant of 1/90 (w/w); this 
dose of Cremophor-EL is well documented 
to cause serious side effects, including hyper-
sensitivity reactions, nephrotoxicity, cardio-
toxicity and neurotoxicity [7,8]. Although 
Abraxane has several practical advantages 
over Taxol, such as the significant reduction 
of toxicity and the increase in the efficiency 
of PTX loading, Abraxane did not improve 
the PK of PTX [9,10]. Additionally, there is no 
evidence that either Abraxane or Taxol can 
overcome multiple drug resistance (MDR) 
in cancer. Many efforts have been made to 
improve the PK of PTX; for example, Sonus 
Pharmaceuticals developed an injectable, 
PEGylated PTX nanoemulsion (NE) with 
vitamin E (VE) as the oil-core. However, this 
NE failed in a pivotal phase III study con-
ducted in breast cancer patients [11]. Letch-
ford K and Burt HM designed copolymers 
composed of higher molecular weight hydro-
phobic blocks that form nanoparticles (NPs). 
These so-called ‘frozen core’ particles were 
expected to better retain PTX, thus leading 
to prolonged circulation of the drugs. Unfor-
tunately, their results indicated PTX was still 
eliminated from the blood rapidly due to 
instability of the carrier upon injection [12]. 
Therefore, the rational design of NPs should 
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Figure 1. Schematic representation of the development of tunable nanoparticles based on molecular-matched 
materials. The molecular-matched NPs that are assembled through the molecular-matched materials achieve much 
higher drug-loading efficiency compared with the mismatched NPs (traditional NPs). Upon entry into circulation, 
the molecular-matched conjugates are stabilized due to the strong interaction with the lipid core, which ensures 
the efficient delivery of the loaded drugs to the targeted tumor tissues. In the case of the mismatched NPs 
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be made based on a sound understanding of the prob-
lems that could arise from poor compatibility between 
cargo and the core of the NPs.
In order to improve the compatibility between the 
cargo and the core of the NPs, we developed molec-
ular-matched NPs based on our technique of molecu-
lar-matched materials (MMMs). These materials were 
synthesized by conjugating a functional molecule to a 
molecule representative of the core of the NPs; func-
tional molecules include drugs, fluorescent imaging 
probes or PEG (Figure 1). The molecular-matched NPs 
were then formulated using MMMs. We hypothesized 
that the solubility of these MMMs would be increased 
due to more favorable interactions with the particle 
core, which would effectively anchor the functional 
molecules to the particle. This could provide the benefit 
of preventing premature drug release, and the PEG sta-
bilization could allow prolonged PK profiles for improv-
ing therapeutic outcomes. We then applied the MMMs 
to create molecular-matched NPs including NEs and 
liposomes. These nanoparticles were then examined for 
their ability to deliver either molecular-matched or mis-
matched agents, hydrophobic drugs, PEG derivatives 
and hydrophilic fluorescent imaging probes.
Materials & methods
Materials
PTX (3H-labeled) was purchased from LC Laboratories 
(MA, USA). D-α tocopheryl polyethylene glycol 1000 
succinate (TPGS) was purchased from Eastman (Ang-
lesey, UK). 1,2-dioleoyl-sn-glycero-3-phosphocholine, 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[amino(polyethylene glycol)-2000] (DSPE-PEG2000) 
and 1,2-distearoyl-sn-glycero-3-phosphoethanol-
amine-N-[poly(ethylene glycol)2000-N’-carboxyfluo-
rescein] (DSPE-PEG2000-CF) were purchased from 
Avanti Polar Lipids. Sulforhodamine acid chloride 
(SRB), (+)-α-tocopherol (VE), D-α-tocopherol suc-
cinate and linoleic acid (LA) were purchased from 
Sigma-Aldrich (MO, USA). PTX conjugated com-
pounds [13,14], SRB conjugated compounds [15], and 
VE PEGylated compounds [16,17] were synthesized by 
our previous methods or other literatures.
Solubility measurements
The solubility of PTX, VE-PTX and LA-PTX in VE 
and LA was determined using a saturation method. 
Briefly, excess PTX or PTX conjugates (trace amount 
of 3H-PTX or 3H-PTX-LA was mixed inside) in chloro-
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Figure 2. The development of vitamin E-paclitaxel molecular-matched nanoemulsions. (A) The molecular structure 
of VE-PTX and LA-PTX. (B) Increased folds of solubility of VE-PTX and LA-PTX compared with free PTX. (C) TEM 
images of VE-PTX NEs (VE-PTX/VE/TPGS = 160/900/360, w/w). (D) The average particle size and size distribution 
of VE-PTX NEs (pH 7.4 PBS as solvent, 1.6 mg/ml VE-PTX NEs were diluted about 50-fold) were determined by 
quasielastic laser light scattering with a Malvern Zetasizer at 25°C (n = 3). (E) TEM images of PTX NEs (PTX/VE/
TPGS = 10/900/360, w/w).  
LA-PTX: Linoleic acid-paclitaxel; NE: Nanoemulsion; TEM: Transmission electron microscopy; TPGS: D-α tocopheryl 
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form was mixed with a VE or LA chloroform solution. 
The chloroform was then evaporated using a nitrogen 
gas flow keeping the mixtures under a vacuum in a 
desiccator for 12 h. The mixtures were centrifuged for 
3 h at a speed of 10,000 rpm and the supernatant oil 
was extracted. The same method was applied to deter-
mine the solubility of SRB, VE-SRB and LA-SRB in 
VE or LA. The amounts of PTX and VE-PTX were 
quantified using a liquid scintillation analyzer, and 
LA-PTX was quantified using HPLC. SRB, VE-SRB 
and LA-SRB were quantified using a fluorescence spec-
trophotometer (λ
ex
 = 560 nm, λ
em 
= 584 nm). 3H-PTX 
and 3H-PTX-VE were used to detect the solubility of 
PTX and VE-PTX, and the solubility of LA-PTX was 
detected using HPLC [13].
Preparation of molecular-matched 
nanoparticles
All molecular-matched NPs were prepared using the 
same preliminary treatment followed by different post-
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Figure 3. In vitro dissolution studies of cargo and PEGylated molecules. (A) In vitro dissolution profiles of PTX and 
VE-PTX (n = 3). PTX emulsions (PTX/VE/TPGS = 5/900/360, w/w); VE-PTX NEs (VE-PTX/VE/TPGS = 100/900/360, 
w/w); VE-PTX NEs using LA as the core (VE-PTX/LA/TPGS = 10/900/360, w/w). (B) In vitro DSPE-PEG2000-CF release 
from the NEs using the dialysis method (n = 3). The NEs of VE or oleic acid (VE or oleic acid/DSPE/DSPE-PEG/DSPE-
PEG-CF=200/80/20/1, w/w) were prepared using the same method.  
DSPE-PEG2000-CF: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[poly(ethylene glycol)2000-N’-
carboxyfluorescein]; LA: Linoleic acid; NE: Nanoemulsion; PTX: Paclitaxel; TPGS: D-α tocopheryl polyethylene 
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processing approaches. Preliminary treatment involved 
dissolving the individual components in chloroform 
that was then evaporated with a nitrogen gas flow. 
Trace amounts of chloroform were removed by keeping 
the mixtures under a vacuum in a desiccator for 1–2 h. 
For emulsions, some Zirconium Oxide beads (a third 
is 1.0 mm diameter and two-third is 0.5 mm diam-
eter) and pH 7.4 phosphate buffer saline (PBS) were 
put into the Rino™ 1.5 ml screw-cap tube with the 
mixtures included. The mixtures were homogenized 
in the Bullet Blender (Next Advance, Inc.) set at the 
8th speed for 8 min to form emulsions. To formulate 
the liposomes, the mixtures of lipids in the flask were 
dried as a thin layer and then hydrated in water while 
the temperature of the suspension was kept at approxi-
mately 80°C. The lipid dispersion was then sonicated 
for 2 min (probe sonicator, output power 10 W, Fisher 
Scientific). 3H-labeled nanoformulations were prepared 
by mixing a trace amount of 3H-PTX, 3H-PTX-VE or 
3H-PTX-LA in the mixtures as preliminary treatment.
Transmission electron microscopy images
Transmission electron microscopy (TEM) images of all 
the NPs were acquired using a JEOL 100CX II TEM. 
Prepared samples (5 μl) were dropped onto a 200 mesh 
carbon-coated copper grid (Ted Pella, Inc., CA, USA) 
and allowed to stand for 5 min, and excess liquid was 
wicked off. Grids were then stained with 1% uranyl 
acetate (5 μl) for 10–15 sec and wicked dry. All images 
were acquired at an accelerating voltage of 100 kV.
In vitro release experiments
Dissolution profiles of PTX or VE-PTX from NEs 
were determined using dialysis technique. Two milli-
liters of NEs (5 mg/ml, calculated as PTX) were added 
in a dialysis membrane with a molecular weight cutoff 
of 12,000–14,000 Da, sealed from both ends and sus-
pended in 200 ml of PBS solution or FBS (fetal bovine 
serum) solution under the agitation of 100 rpm using 
a paddle at 25°C. At predetermined time intervals (0, 
0.5, 1, 2, 3, 4, 6, 8, 12, 24 and 32 h), 100 μl of medium 
was withdrawn and fresh medium was complemented. 
3H-labeled PTX and VE-PTX were quantified on a liq-
uid scintillation analyzer (TRI-CARB, Packard Biosci-
ence Company, MA, USA). In vitro DSPE-PEG2000-
CF release from the NEs was determined using a similar 
method. The difference between the two methods was 
that the beaker was put in a shaker at 25°C. The samples 
were kept in the dark and analyzed using a fluorescence 
spectrophotometer (λ
ex 




Female CD-1 mice (18–22 g) received injections of 
16 mg/kg of VE-PTX (or 10 mg/kg of PTX) into 
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Figure 4. Pharmacokinetic studies of molecular-matched and molecular-mismatched emulsions. (A) The PK 
profiles of PTX emulsion and VE-PTX PEGylated NEs (n = 3). The mice were injected intravenously with different 
formulations (equal dose of 10 mg PTX/kg) containing 2 μCi 3H labeled PTX (or 3H labeled PTX-VE). PTX emulsions 
(PTX/VE/TPGS/VE2-PEG2000 = 5/900/288/110, w/w); VE-PTX/TPGS NEs (VE-PTX/VE/TPGS = 100/900/340, w/w). 
All other VE-PTX PEGylated NEs contained the same molar ratio with VE-PTX/TPGS NEs, except that 20% mol 
TPGS was replaced with VE-PEG2000, DSPE-PEG2000 and VE2-PEG2000. (B) PK comparison between VE-PTX NEs 
PEGylated with VE-O-PEG2000 and VE-PEG2000 (n = 3). The mice were injected intravenously with the dose 
of 16 mg VE-PTX/kg containing 2 μCi 3H labeled PTX-VE. VE-PTX NEs (VE-PTX/VE/TPGS/VE2-(O)-PEG2000 = 
100/900/288/90, w/w).  
DSPE-PEG2000: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000]; 
NE: Nanoemulsion; PK: Pharmacokinetic; PTX: Paclitaxel; TPGS: D-α tocopheryl polyethylene glycol 1000 succinate; 
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the tail vein. Each mouse received 2 μCi of radiola-
beled drugs. The volume injected into each mouse 
was approximately 0.2 ml. After injection, samples of 
10–20 μg of blood was collected at each time point. 
Blood samples were digested in 0.2 ml of tissue solu-
bilizer (Amersham Biosciences). Two-hundred micro-
liters of 30% hydrogen peroxide was added to the sam-
ples for decolorization. A scintillation cocktail (Ultima 
Gold™ XR, PerkinElmer, MA, USA) was added to 
the decolorized samples and stored in the dark to 
allow any chemiluminescence to subside. The radio-
activity was then quantified on a liquid scintillation 
analyzer (TRI-CARB, Packard Bioscience Company, 
MA, USA). The concentration of drugs in the samples 
was determined from the net intensity of radioactivity 
obtained by subtracting the intensity of radioactivity 
of the blank based on the standard calibration curve. 
Pharmacokinetic parameters were according to a non-
compartmental PK model calculated by DAS 2.1.1 
software.
Antitumor efficacy
To create the MDR tumor model, 5 × 106 KB-8–5 cells 
were injected subcutaneously into the right flanks of 
nude mice. Once the tumor mass in the xenograft was 
established, mice were randomly divided into different 
treatment groups and intravenously injected with dif-
ferent formulations of VE-PTX at a dose of 16 mg/kg 
(10 mg/kg PTX). The weight of the mice was moni-
tored after they had received treatment. Tumor volume 
was calculated by the formula: (length × [width]2)/2. 
Animals were treated in accordance with National 
Institute of Health Guide for the Care and Use of 
Laboratory Animals as approved by the University of 
North Carolina at Chapel Hill Institutional Animal 
Care and Use Committee.
In vivo distribution test
KB-8–5 tumor-bearing mice were intravenously 
injected with Taxol or molecular-matched VE-PTX 
NE at doses of 10 mg/kg. At 240 min after injection, 
animals were sacrificed and a kidney, lung, spleen, 
heart and 50–100 mg of liver and tumor were collected. 
The organs were washed twice with PBS and wiped. 
The samples were digested using tissue solubilizer, and 
quantified on liquid scintillation analyzer.
In vivo imaging
Free SRB and molecular-matched LA-SRB-loaded 
liposomes were intravenously injected through the 
tail vein of SKOV3 (human ovarian carcinoma cell) 
tumor-bearing mice (5 mg SRB/kg of or the same 
molar LA-SRB). The mice were imaged under anes-
thesia for several times after injection using a Kodak 
In-Vivo FXPro imaging system. The organs, including 
the heart, liver, spleen, lungs, kidneys, intestines, colon 
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Figure 5. Antitumor effects in KB-8–5 multiple drug resistance tumor-bearing mice. The mice were intravenously 
injected with the VE-PTX NEs or Taxol or blank NEs every 3 days for five consective injections. The tumor volume 
(A) and the mice weight (B) were determined (the mice were sacrificed 18 days after the first injection). The VE-
PTX NEs were formulated with VE-PTX/VE/TPGS/VE2-PEG2000=100/900/288/110 (w/w).  
#No significant difference; *p < 0.05; **p < 0.01 (n = 5).  
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and tumor were collected 8 h after injection and also 
imaged.
Results & discussion
Increased compatibility between PTX & VE by 
the MMMs
Among the biocompatible oils, tocopherol (VE) has a 
relatively high capacity to dissolve PTX. This discov-
ery led to the development of the injectable PTX NEs 
from Sonus Pharmaceuticals. However, despite an abil-
ity to dissolve PTX, the PK from these NEs demon-
strated that VE was not able to retain PTX within the 
core. This led to a rapid loss of PTX from the system 
and consequently poor efficacy. Consequently, solubil-
ity alone is not highly predictive of PK outcomes. Drug 
partitioning is a ratio of favorability between the two 
phases comprising an interface. Thus drug retention 
will depend on maximizing the favorability for the 
emulsion core compared with water, protein surfaces 
and cell membranes from endothelial cells or eryth-
rocytes. To prove the concept that the compatibility 
between PTX and VE can be enhanced through the 
MMMs, we conjugated PTX to VE or LA (Figure 2A). 
The solubility of PTX as well as the VE–PTX and 
LA–PTX conjugates in either VE or LA was exam-
ined. The solubility of PTX in VE and LA was 46.6 
and 2.8 μmol/ml, respectively. As PTX was conjugated 
with VE or LA, the solubility increased to 298.7 μmol/
ml (VE-PTX in VE) and 21.0 μmol/ml (LA-PTX 
in LA). The enhanced solubility demonstrates the 
molecular-matched pattern: the increased solubility 
of VE-PTX in VE greater than VE-PTX in LA and 
the solubility of LA-PTX in LA greater than LA-PTX 
in VE (Figure 2B). The molecular-matched NEs were 
formulated to deliver the molecular-matched prodrug 
(VE-PTX), with an encapsulation efficiency of >98% 
and a particle size of 70.5 ± 4.8 nm (Figure 2C & D). In 
contrast, the VE emulsion carrying free PTX showed 
both large-size particles and crystal precipitation 
(Figure 2E). The molecular-matched NEs were stable 
in a week at an ambient temperature (no precipitation 
and no change in particle size), and even remained a 
transparent solution after 3 months of storage at 4°C. 
The VE emulsion on the other hand becomes turbid.
Controlled release & minimized PEG-shedding 
by the MMMs
To efficiently deliver a drug to the tumor tissues, NPs 
must compactly house the loaded drugs during circu-
lation with minimal or no drug release. We hypoth-
esized that the stability of PTX in the VE cores could 
be greatly improved through the use of the MMMs 
technique because of a decreased crystallinity of the 
PTX-VE prodrug and improved interactions between 
the core and the molecular-matched conjugates. As 
shown in Figure 3A, a quick release of PTX from the 
VE NEs was observed; the accumulated PTX that 
was released in PBS reached 50% in 8 h. However, 
<2% of the molecular-matched VE-PTX NEs in 
PBS and <3% of the molecular-matched VE-PTX 
NEs in 5% FBS were released in 32 h. As expected, 
mismatched VE-PTX in LA NEs was released more 
quickly than the correctly matched VE-PTX in VE 
NEs. These data indicate that stable drug-residence 
and adjustable drug release can be achieved using the 
MMMs.
www.futuremedicine.com 3009
Figure 6. In vivo biodistribution of Taxol and VE-
PTX molecular-matched NEs (VE-PTX/VE/TPGS/VE2-
PEG2000=100/900/288/110, w/w) at 6 h postinjection 
in KB-8–5 tumor-bearing mice (n = 5). 
NE: Nanoemulsion; TPGS:D-α tocopheryl polyethylene 
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In addition to obtaining stable drug residence in the 
NPs, the retention of the PEG coating on the surface of 
NPs is also important. The dissociation of PEG deriva-
tives (shedding) from the liposomal membrane was 
first reported by Cullis [18]. To assess if using MMMs 
could minimize PEG shedding in vitro, the core of 
the NEs was adjusted to match (or mismatch) the two 
18-carbon tails of DSPE-PEG2000-CF (carboxyfluo-
rescein) (Avanti Polar Lipid) and the amount of dis-
sociation of the DSPE-PEG2000-CF was determined. 
As shown in Figure 3B, less than 2% of PEG shedding 
in PBS was detected for both the molecular-matched 
(oleic acid as the core) and mismatched (VE as the 
core) PEGylated NEs. In 5% FBS, increased shed-
ding of PEG was observed, but the molecular-matched 
PEGylated NEs exhibited a shedding of PEG that was 
much slower than that of the mismatched PEGylated 
NEs (17 vs 57% release in 32 h).
Manipulate the PK of NEs with molecular-
matched & molecular-mismatched agents
To assess if the PK of loaded PTX or VE-PTX in 
PEGylated NEs could be improved using the MMMs, 
we conjugated VE to PEG, creating VE-PEG2000 and 
VE
2
-PEG2000, which contained two VE tails. When 
free PTX was carried by the emulsion PEGylated with 
the VE
2
-PEG2000, the PK was much shorter than 
that of any VE-PTX PEGylated NEs (Figure 4A). This 
was attributed to poor compatibility between PTX 
and VE. The PK of the VE-PTX NEs PEGylated 
with VE
2
-PEG (molecular-matched, two VE tails) 
was much longer than those of the VE-PTX NEs 
PEGylated with DSPE-PEG2000 (mismatched, two 
lipid tails) and VE-PEG2000 (molecular-matched, 
a VE tail). These data indicate, in addition to the 
molecular-matched, the two lipid-tails of the PEG 
derivatives may prolong the PK more efficiently than a 
single lipid-tail, putatively because of increased interac-
tions with the particle core. We also loaded LA-PTX 
as a molecular-mismatched cargo in the VE core of the 
NEs PEGylated with the VE
2
-PEG2000 and exam-
ined its PK. As the molecular-matched VE-PTX was 
replaced by molecular-mismatched LA-PTX, the PK of 
the LA-PTX NE became shorter than that of VE-PTX 
NEs. This further confirms the molecular-matched 
cargo plays an important role in cargo retention. All 
the data above demonstrate that the desired PK can 
be achieved by modifying both the lipid anchor of 
the PEG derivatives and the therapeutic (or imaging) 
agents to be molecular-matched to the carrier. It also 
suggests the possibility of designing the NEs with a 
tunable PK using the MMMs (Table 1). Additionally, 
we synthesized VE-O-PEG2000, in which VE was 
Table 1. Pharmacokinetic parameters of paclitaxel and vitamin E-paclitaxel and linoleic acid-paclitaxel after 
intravenous injection (n = 3).
Parameters VE2-PEG2000 NEs DSPE-PEG2000 
NEs
VE2-PEG2000 NEs VE-PEG2000 
NEs
TPGS NEs VE2-PEG2000 
NEs
 VE-PTX VE-PTX LA-PTX VE-PTX VE-PTX PTX
AUC(0-t) (mg/l h) 2220.94 ± 199.37 1414.86 ± 104.39 2596.68 ± 295.4 379.67 ± 60.38 313.20 ± 25.39 6.17 ± 2.35
AUC(0-∞) (mg/l h) 3208.76 ± 117.10 1415.41 ± 104.3 3397.68 ± 1036.62 381.64 ± 60.52 315.7 ± 25.84 6.38 ± 2.44
MRT(0-t) (h) 7.2536 ± 0.24 9.71 ± 0.32 16.62 ± 0.55 3.69 ± 0.11 3.31 ± 0.09 1.24 ± 0.04
MRT(0-∞) (h) 15.51 ± 1.29 9.72 ± 0.33 31.70 ± 14.04 3.79 ± 0.11 3.45 ± 0.11 1.45 ± 0.08
t1/2 (h) 10.99 ± 0.94 4.26 ± 0.13 23.97 ± 10.60 2.81 ± 0.09 3.23 ± 0.11 1.30 ± 0.11
CL (l/h/kg) 0.004 ± 0.000 0.010 ± 0.001 0.004 ± 0.001 0.036 ± 0.006 0.043 ± 0.004 2.351 ± 0.972
VD (l/kg) 0.07 ± 0.01 0.06 ± 0.01 0.13 ± 0.02 0.15 ± 0.03 0.20 ± 0.01 4.49 ± 1.95
Cmax (mg/l) 220.52 ± 13.79 217.27 ± 20.27 248.76 ± 8.11 216.07 ± 39.24 199.11 ± 8.25 4.51 ± 1.35
CL: Total body clearance; DSPE-PEG2000: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000]; MRT: Mean retention time; 
NE: Nanoemulsion; t
1/2: 
Half-life; TPGS: D-α tocopheryl polyethylene glycol 1000 succinate; VD: Volume of distribution; VE: Vitamin E.
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Figure 7. The solubilities of hydrophilic fluorescent imaging molecule, sulforhodamine acid chloride and its 
conjugates. (A) Solubility of SRB and SRB conjugates in VE or LA (top) and imaging of the saturated solution 
(bottom). The solubility of free SRB, the conjugates of VE-SRB and LA-SRB were quantified using a fluorescence 
spectrophotometer (λex = 560 nm, λem = 584 nm). Photos were taken of the saturated solutions of VE and LA 
containing free SRB or the conjugates. (B) Increase in solubility of SRB conjugates compared with free SRB.  
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linked to PEG2000 through an ether bond. An ether 
bond is more biologically stable than an ester bond. 
The NEs PEGylated with VE-O-PEG2000 showed 
a similar PK to that of the ester bond linked VE-
PEG2000 (Figure 4B), indicating that de-PEGylation 
of the NEs is due to the PEG derivatives shedding, not 
the ester bond hydrolysis.
Deliver the molecular-matched NEs to treat 
multidrug resistance in cancer
The molecular-matched NEs have an ability to circulate 
for a long time leading to preferential accumulation of 
the NE within the tumor tissues via the enhanced per-
meability and retention (EPR) effect. To evaluate the in 
vivo antitumor efficacy, KB-8–5 MDR tumor-bearing 
mice were intravenously injected with the VE-PTX NEs 
or Taxol every 3 days. The administration of Taxol did 
not induce any noticeable inhibition of MDR tumor 
growth (Figure 5A). A significant regression of MDR 
tumors was observed in mice treated with the VE-PTX 
NEs, indicating that the VE-PTX NEs using VE as the 
core can efficiently sensitize MDR tumors. The signifi-
cant in vivo efficacy might be explained by two occur-
rences: one is the enhanced accumulation of molecular-
matched NEs at the tumor site due to long circulation 
(Figure 6), and second that VE and TPGS could induce 
a significant reversal of MDR. In fact, we found that 
VE is the key structure of TPGS, responsible for inhibit-
ing P-gp [19]. As for tolerability, no weight loss occurred 
in the mice treated with the VE-PTX NEs (Figure 5B). 
Changes in the serum aspartate aminotransferase, ala-
nine aminotransferase and blood urea nitrogen levels, 
which are commonly used as biochemical markers for 
liver and kidney function, were also examined. The 
alanine aminotransferase and aspartate aminotrans-
ferase were significantly elevated in the group treated 
with Taxol but not with the VE-PTX NEs (Table 2). 
Taken together, the results indicated that in addition to 
increased efficacy and MDR sensitization, the VE-PTX 
NEs are much better tolerated than Taxol.
Table 2. Kidney and liver function parameters in the different experimental group (n = 5).
Formulation AST(U/l) ALT(U/l) BUN/(mg/dl)
Control 133.8 ± 9.7 65.8 ± 17.3 22.4 ± 1.5
Taxol 217.2 ± 54.4 99.2 ± 19.4 24.6 ± 1.5
PTX-VE NEs 125.9 ± 23.2* 57.6 ± 3.5* 23.6 ± 2.5
Normal range 54–298 17–77 8–33
*p < 0.01
Values are given as mean ± standard deviation.
Serum samples were collected after mice received four-times 10 mg/kg Taxol or 16 mg/kg VE-PTX NEs every other day.
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase, BUN: Blood urea nitrogen; VE-PTX: Vitamin E-paclitaxel.
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Figure 8. In vivo images of free SRB and LA-SRB molecular-matched liposomes (DOPC/LA/DSPE-PEG2000/LA-
SRB =1000/500/280/80, w/w). The mice were injected intravenously with either free SRB or LA-SRB molecular-
matched liposomes (5 mg SRB/kg). Photos were taken at the indicated time-points using the Kodak In-Vivo FXPro 
imaging system (λex = 500nm, λem = 600nm) (A). Ex vivo biodistribution of free SRB and LA-SRB molecular-matched 
liposomes in mice. The mice were sacrificed 8 h after injection and the organs were collected and imaged (B).  
DOPC: 1,2-dioleoyl-sn-glycero-3-phosphocholine; DSPE-PEG2000: 1,2-distearoyl-sn-glycero-3-
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Establish molecular-matched liposome to 
deliver water soluble fluorophore for  
tumor-imaging
To assess if the compatibility between hydrophilic mol-
ecules and oil can be also enhanced using the MMMs, 
a water-soluble SRB was conjugated to VE or LA. As 
shown in Figure 7A, the solubility of SRB in oil was 
improved by the conjugation, which increased from 
0.77 μmol/ml (SRB) to 33.2 μmol/ml (VE-SRB) 
in VE and increased from 0.48 μmol/ml (SRB) to 
46.7 μmol/ml (LA-SRB) in LA. The enhanced solu-
bility also showed the core-dependence (Figure 7B), 
i.e., the solubility of VE-SRB in VE > in LA (33.2 vs 
8.4 μmol/ml) and LA-SRB in LA > in VE (46.7 vs 
23.6 μmol/ml).
We also developed molecular-matched liposomes 
using the MMMs for tumor imaging. Very few studies 
have reported the successful encapsulation of water-
soluble fluorophores in liposomes for the purpose of 
in vivo imaging of tumors. The low-loading efficiency 
is most likely the cause of this setback. Improving 
the affinity and compatibility of SRB to the LA lipid 
using the MMMs allows us to encapsulate LA-SRB 
in liposomes for imaging of tumors. The molecular-
matched liposomes were prepared through the inclu-
sion of LA in the liposomes to provide the molecular-
matched environment for LA-SRB. The particle size 
of LA-SRB liposomes remained unchanged (110.5 ± 
7.7 nm) at 4°C after 1 month of storage. Whole-body 
imaging in tumor-bearing mice (Figure 8A) showed 
that no fluorescence was detectable in the tumors 
after injection with free SRB. However, the SRB sig-
nal was detected in the tumors 1 h after the injection 
of the molecular-matched liposomes. The detectable 
florescent-signal in the tumors lasted for as long as 
2 days postinjection (no signal was detected on day 
3). While the colon and liver were the major organs 
taking up the liposomes (Figure 8B), the whole-body 
imaging failed to detect this pattern because of the 
shallow tissue penetration of fluorescence imaging. 
The light tissue penetration can be improved using 
a near-infrared fluorescent dye, such as indocyanine 
green.
Conclusion
Rationally designed nanocarriers would benefit from 
an ability to carry both hydrophobic and hydrophilic 
bioactive materials, prevent drugs from interacting 
with the biological environment during circulation and 
control the PK and drug release profiles. The presented 
molecular-matched NPs have demonstrated high-drug 
loading capacity for hydrophobic drugs as well as a 
hydrophilic imaging probe. The MMMs also could 
be applied to maintain stable residence of both the 
drugs and probes within the core during circulation. 
Furthermore, the development of molecular-matched 
NPs based on MMMs emphasizes the importance of 
‘matching’ to the stability of the NPs.
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Future perspective
The developed NEs are composed of entirely gener-
ally recognized as safe materials to facilitate the clinical 
translation of the delivery systems. While the molec-
ular-matched conjugates of the VE-PTX (prodrug) 
and VE-PEG reported here are new derivatives, they 
are not new chemical entities. The VE, PTX and PEG 
derivatives are currently being used clinically. The 
reformulation of these MMMs may provide a powerful 
tool to improve the disposition of drugs without affect-
ing clinical translation. More importantly, the MMMs 
show the versatility to be utilized in the design of tai-
lored, multifunctional theranostic NPs, which could 
be even more valuable as this nascent field begins to 
grow in importance.
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Executive summary
Background
•	 The compatibility between the cargo and the core of the nanoparticles should be emphasized to investigate as 
designing nanomedicine.
Materials & methods
•	 Molecular-matched materials are established through the conjugation of the functional moiety to a molecule 
representative of the nanoparticle’s core.
Results & discussion
•	 The developed nanoemulsion using molecular-matched materials showed good in vitro stability.
•	 The molecular-matched PEGylated nanoemulsions (NEs) exhibited a shedding of PEG that was much slower 
than that of the mismatched PEGylated NEs.
•	 The pharmacokinetics of the cargo encapsulated in the nanoparticles could be manipulated through adjusting 
the compatibility between the core of the nanoparticles and the drug or PEGylated molecule.
•	 Enhanced accumulation of molecular-matched nanoemulsions at the tumor site was achieved due to the long 
circulation characteristics of the NEs.
•	 Vitamin E-paclitaxel NEs using vitamin E as the core can efficiently sensitize multiple drug resistance tumors 
when compared with Taxol.
•	 The established molecular-matched liposome also showed good in vivo imaging ability.
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